Table 4.
Perkins [10]; (%) | Kanski [15]; (%) | Giles [2]; (%) | Tugal-Tutkun [3]; (%) | Soylu [13]; (%) | Kadayıfçılar [12]; (%) | Current Study | |
---|---|---|---|---|---|---|---|
Pars planitis | – | – | – | 15.3 | 8.9 | 11.87 | 24 |
Idiopathic | 43.3 | 5.8 | 60 | 21.5 | 34.4 | 24.2 | 16.5 |
Behcet’s disease | – | 0.5 | – | 0.7 | 11.1 | 10.96 | 16.5 |
Toxoplasmosis | 20.6 | – | – | 7.7 | 25.6 | 21 | 13.2 |
JIA | 5.3 | 76.7 | 20 | 41.5 | 3.3 | 13.24 | 6.6 |
Herpetic uveitis | 3.3 | – | 3.4 | – | 3.3 | 2.74 | 4.1 |
Toxocara | 10 | – | – | 3.1 | 1.1 | 3.2 | 3.3 |
Ankylosing spondylitis | 0.6 | 12.7 | 1.3 | 0.7 | – | 1.83 | 4.1 |
Fuch’s uveitis | 2.6 | – | 3.9 | 0.7 | 5.6 | 4.11 | 2.5 |
Brucella | 0.8 | ||||||
Sarcoidosis | 2.6 | 0.8 | 3.9 | 2.3 | – | 0.91 | 0.8 |
FMF | 1.6 | ||||||
VKH | 0.6 | 0.2 | – | 1.5 | – | 0.46 | 0.8 |
Tuberculosis | 3.3 | – | 1.7 | – | – | 1.37 | – |
JIA juvenile idiopathic arthritis, FMF Familial Mediterranean Fever, VKH Vogt–Koyanagi–Harada disease